Items Tagged ‘SLAMF7’

December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7